By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Zander Therapeutics, Inc. 

4700 Spring Street
Suite 304
La Mesa  California  91942  U.S.A.
Phone: 619-702-1404 Fax: 619-330-2328


Zander Therapeutics, Inc. is a veterinary biotechnology company that is wholly owned by Entest BioMedical Inc. (a publicly traded company -- OTCPINK: ENTB). Zander is focused on developing veterinary treatments for cancer and autoimmune disorders (such as arthritis). We are targeting canine cancer, especially considering that 50% of all dogs over the age of 10 years will develop some form of cancer. Feline Leukemia (FL) is another focal point, with 2-3% of all cats in the United States carrying the feline leukemia virus. Additionally, we are looking at arthritis in animals from dogs and cats to thoroughbred horses.


CEO: David R. Koos

CSO: Harry Lander

CFO: Todd S. Caven


Please click here for Zander Therapeutics job opportunities.

Key Statistics

Ownership: Subsidiary

Web Site: Zander Therapeutics, Inc.


Company News
Zander Therapeutics, Inc. Announces Appointment Of Dr. Robin Beat Gasser To Scientific Advisory Board 9/13/2017 8:03:15 AM
Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression Of IL-17a And IL-2 In Dogs With Novel NR2F6 Activators 7/26/2017 10:42:42 AM
Zander Therapeutics, Inc. Announces Brian Devine, Former Chairman Of PETCO, To Helm Its Business Advisory Board 6/27/2017 11:45:22 AM
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed The Production Of Multiple Cytokines Known To Be Involved In Inflammation With No Toxicity In Canine Studies 6/14/2017 8:32:46 AM
Entest Biomedical, Inc.'s Subsidiary EnteroMedics (ETRM) Reports On Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds 6/7/2017 10:07:23 AM
Entest Biomedical, Inc. Subsidiary Zander Therapeutics, Inc. Discusses Developments In Medicinal Chemistry For Veterinary Applications Of Cancer And Autoimmune Therapies Through Modulation Of Checkpoint NR2F6 5/24/2017 8:07:25 AM
Entest Biomedical, Inc.'s Chairman Discusses Its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies For Treating Cancer And Arthritis In Dogs 4/27/2017 11:55:43 AM
Entest Biomedical, Inc.'s Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies On Modulating NR2F6 In Canines 4/19/2017 8:32:03 AM
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc. Announces Appointment Of Dr. Thomas Donnelly To Serve As Senior Veterinary Advisor 3/9/2017 11:38:14 AM
Entest Biomedical, Inc.'s Zander Therapeutics, Inc. Unit Announces Publication Of Canine Cellular Immunotherapy Patent Application For Treating Cancer In Dogs 2/15/2017 6:43:37 AM